

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/754,775
Filing Date	January 4, 2001
First Named Inventor	Grainger, David
Group Art Unit	1617
Examiner Name	Criares, T.J.

Sheet 1 of 2

Attorney Docket No: 00295.009US3

TECH CENTER 160012900

OCT 02 2002

RECEIVED

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date if Appropriate
<i>TR</i>	5,411,988	05/02/1995	Bockow et al.	514	560	10/27/1993
	5,445,941	08/29/1995	Yang	435	6	06/21/1993
	5,446,070	08/29/1995	Mantelle	514	772.6	08/27/1993
	5,496,851	03/05/1996	Grinnell	514	443	04/14/1995
	5,605,700	02/25/1997	DeGregorio et al.	424	448	10/31/1994
	5,652,259	07/29/1997	May	514	422	05/09/1996
	6,410,587	06/25/2002	Grainger et al.	514	445	05/05/2000

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
<i>TR</i>	EP 0 377 526	07/11/1990	Abdel-Monem et al.	C07F	1/08	
	EP 0 675 103	10/04/1995	Horrobin et al.	C07C	69/612	
	EP 0 684 259	11/29/1995	Koyama et al.	C07K	5/09	
	WO 96/21442	07/18/1996	Korsaard et al.	A61K	31/40	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>TR</i>		"Schering/Orion <i>Fareston</i> Anti-Estrogen for Treatment of Metastatic Breast Cancer 'Similar' to Tamoxifen, FDA Oncologic Committee Says in Approval Vote", <i>F-D-C Reports</i> , 15-16 (1995).	
		HARDCASTLE et al., "Homologs of Idoxifene: Variation of Estrogen Receptor Binding and Calmodulin Antagonism with Chain Length", <i>J. Med. Chem.</i> , 39 , 999-1004 (1996).	
		HAYES et al., "Randomized Comparison of Tamoxifen and Two Separate Doses of Toremifene in Postmenopausal Patients with Metastatic Breast Cancer", <i>Journal of Clinical Oncology</i> , 13 , 2556-2566 (1995).	
		JONES et al., "Increased Susceptibility to Metal Catalysed Oxidation of Diabetic Lens β_L Crystallin: Possible Protection by Dietary Supplementation with Acetylsalicylic Acid", <i>Exp. Eye Res.</i> , 57 , 783-790 (1993).	
		LOSER et al., "In Vivo and in Vitro Antiestrogenic Action of 3-Hydroxytamoxifen, Tamoxifen and 4-Hydroxytamoxifen", <i>Eur. J. Cancer Clin. Oncol.</i> , 21 , 985-990 (1985).	

EXAMINER

DATE CONSIDERED

6/30/02

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete, if Known

Application Number	09/754,775
Filing Date	January 4, 2001
First Named Inventor	Grainger, David
Group Art Unit	1617
Examiner Name	Criares, T.J.

Sheet 2 of 2

Attorney Docket No: 00295.009US3

RECEIVED
OCT 02 2002
TECH CENTER 1600/2902

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
JK		MOORTHY et al., "Tamoxifen Metabolic Activation: Comparison of DNA Adducts Formed by Microsomal and Chemical Activation of Tamoxifen and 4-Hydroxytamoxifen with DNA Adducts Formed in Vivo", <u>Cancer Research</u> , 56 , 53-57 (1996).
		MURPHY et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation <i>in Vitro</i> ", <u>Endocrinology</u> , 116 , 1071-1078 (1985).
		MURPHY et al., "Structure-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: Importance of Hydroxyl Group and Side Chain Positioning for Biological Activity", <u>Molecular Pharmacology</u> , 39 , 421-428 (1991).
		SARGENT et al., "Induction of Hepatic Aneuploidy <i>in Vivo</i> by Tamoxifen, Toremifene and Idoxifene in Female Sprague-Dawley Rats", <u>Carcinogenesis</u> , 17 , 1051-1056 (1996).

EXAMINER

DATE CONSIDERED

6/30/03

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional) ‡ Applicant is to place a check mark here if English language Translation is attached